急性冠脉综合征患者行经皮冠状动脉介入术后使用替格瑞洛的疗效与安全性  

Efficacy and safety analysis of ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention

作　　者：赵宝昌 叶雪玲 张吉梅 董宏伟[2] ZHAO Bao-chang;YE Xue-ling;ZHANG Ji-mei;DONG Hong-wei(Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271016, China;Dezhou People's Hospital, Dezhou 253000, China)

机构地区：[1]山东第一医科大学(山东省医学科学院),山东泰安271016 [2]德州市人民医院,山东德州253000

出　　处：《泰山医学院学报》2019年第9期666-668,共3页Journal of Taishan Medical College

摘　　要：目的探讨山东德州地区急性冠脉综合征(ACS)患者行经皮冠状动脉介入术后替格瑞洛的治疗效果与安全性。方法选择入院的急性冠脉综合征患者并成功经皮冠状动脉介入治疗200例患者,随机分为实验组与对照组,分别给予标准剂量的替格瑞洛与氯吡格雷治疗。统计患者的一般资料,随访观察1个月,记录并分析血小板聚集率、术后出血事件发生率、不良反应发生情况。结果与氯吡格雷相比,替格瑞洛抑制血小板聚集效果更显著,但其使患者出血风险和不良反应发生率更高,差异具有统计学意义(P<0.05);而且替格瑞洛的治疗有效率没有提升(P>0.05)。结论对山东德州地区的ACS患者来说,替格瑞洛并未给患者带来明显获益。从药物安全性出发,本地区患者更适合继续使用氯吡格雷。Objective: To investigate the efficacy and safety of ticagrelor in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) in Dezhou, Shandong province.Methods:200 patients , who were affected with acute coronary syndrome and successfully received percutaneous coronary intervention, were selected and randomly divided into experimental group and control group, respectively receiving standard dose of ticagrelor and clopidogrel.The general data of patients were collected, followed up for one month, and the platelet aggregation rate, incidence of postoperative bleeding events and adverse reactions were recorded and analyzed.Results:Compared with clopidogrel, ticagrelor had a more significant effect in inhibiting platelet aggregation, but it caused a higher risk of bleeding and incidence of adverse reactions in patients, and the difference was statistically significant (P<0.05). But the efficacy of ticagrelor was not significantly improved (P>0.05).Conclusion:For the ACS patients in Dezhou, Shandong province, ticagrelor did not provide significant benefits. In terms of drug safety, patients in this region are more suitable to continue using clopidogrel.

关 键 词：抗血小板药物 替格瑞洛 安全性 治疗效果 

分 类 号：R972.6[医药卫生—药品]